• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

(C429-0340)

1

Identification

C429-0340 C429-0340
Name C429-0340
Formula C23H26ClN3O3
MW 427.92
CAS No.
EINECS
Smiles C1C=C(Cl)C(C)=C(NC2C3C=CC=CC=3C(=O)N2C2CCN(C(OCC)=O)CC2)C=1
Synonyms
InChI InChI=1S/C23H26ClN3O3/c1-3-30-23(29)26-13-11-16(12-14-26)27-21(17-7-4-5-8-18(17)22(27)28)25-20-10-6-9-19(24)15(20)2/h4-10,16,21,25H,3,11-14H2,1-2H3
2

Introduction

C429-0340 is a novel cyclin-dependent kinase 8 (CDK8) inhibitor. The inhibition rate is 48.7±2.6% at 10 μM. CDK8 gene expression correlates with increased mortality in colorectal, breast, and ovarian cancers and its overexpression is essential for the proliferation of cancer cells. Due to its key roles in oncogenesis, CDK8 has recently attracted considerable attention. Inhibitors of CDK8 offer a novel strategy for the treatment of various cancers.

Background Information

3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance: EBNumber:EB100692180

Storage condition

Solubility

5

Mechanism and Indication

Signaling Pathways Cell Cycle/DNA Damage
Target CDK
Research Area Cancer
Indications
6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
7

Safety Data of C429-0340

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
AMEDCHEM CHINA
10

Related Products

Other Forms of

Name CAS No Formula MW

Recommended Compounds in CDK

Name CAS No Formula MW
LY2857785 1619903-54-6 C26H36N6O 448.6
THZ2 1604810-84-5 C31H28ClN7O2 566.0527
Palbociclib (isethionate) 827022-33-3 C26H35N7O6S 573.66
CDK9-IN-6 1391855-95-0 C27H37ClN6O2 513.07468
ML167 1285702-20-6 C19H17N3O3 335.36
AMG 925 1401033-86-0 C26H29N7O2 471.55
LDC000067 1073485-20-7 C18H18N4O3S 370.43
LEE011 (succinate hydrate) 1374639-79-8 C27H38N8O6X 570.64
LEE011 (succinate) 1374639-75-4 C27H36N8O5 552.63
LEE011 (hydrochloride) 1211443-80-9 C23H31ClN8O 471.0
LEE011 1211441-98-3 C23H30N8O 434.54
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 333.77
Wogonin 632-85-9 C16H12O5 284.26
1-NM-PP1 221244-14-0 C20H21N5 331.41
WHI-P180 211555-08-7 C16H15N3O3 297.31
THZ1 1604810-83-4 C31H28ClN7O2 566.05
Senexin A 1366002-50-7 C17H14N4 274.32
CDK4-IN-1 1256963-02-6 C22H29ClN8 440.97
Palbociclib (hydrochloride) 827022-32-2 C24H30ClN7O2 483.99
Purvalanol B 212844-54-7 C20H25ClN6O3 432.9

Recommended Compounds in Same Indication

Name CAS No Formula MW
11

Route of Synthesis

12

References

13

More Information

C429-0340

Tags: buy C429-0340 IC50 | C429-0340 price | C429-0340 cost | C429-0340 solubility | C429-0340 purchase | C429-0340 manufacturer | C429-0340 research buy | C429-0340 order | C429-0340 MSDS | C429-0340 chemical structure | C429-0340 Storage condition | C429-0340 molecular weight | C429-0340 mw | C429-0340 datasheet | C429-0340 supplier | C429-0340 cell line | C429-0340 NMR | C429-0340 MS | C429-0340 IR | C429-0340 solubility | C429-0340 Safe information | C429-0340 Qc and Spectral Information | C429-0340 Clinical Information | C429-0340 Clinical Trial | C429-0340 Route of Synthesis | C429-0340 storage condition | C429-0340 diseases and conditions | C429-0340 flash point | C429-0340 boiling point | C429-0340 melting point | C429-0340 storage condition | C429-0340 brand